/
/
Parkinson’s UK

Parkinson’s UK

What is funded:

  • to better understand the causes of Parkinson’s and Parkinson’s like disorders
  • to investigate the potential links between diabetes and Parkinson’s
  • drug discovery at all stages of the drug discovery pipeline
  • cohort studies
  • early clinical investigations looking at biomarkers
  • pilot clinical trials
  • areas of unmet needs

Eligibility:

Co-applicants and collaborators may be based at institutions outside the UK or at pharmaceutical or biotech companies. Grants are tenable only at a UK university, NHS Trust, statutory social care organisation or other UK research institution.

Deadline:

  • Preproposal: January 7th 2026 4pm
  • Full application deadline: April 8th 2026

The duration of a grant is up to a maximum of 36 months.

There is no fixed minimum or maximum value for project grants.

The cost of applications is usually up to £400,000 and the average amount awarded is £260,000.

Share this post

Facebook
Twitter
LinkedIn
WhatsApp

Latest Updates

ercc
ERC

Starting Grant Researchers of any nationality with 2-7 years of experience since completion of PhD, a scientific track record showing great promise and an excellent...

mic

Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation of Research Objective: The Alzheimer’s Association and The Michael J. Fox Foundation...

Untitled-1

ASAP will support higher-risk, large-scale, ambitious projects across two tracks: scientific track and technical track. Scientific: an international, multidisciplinary, multi-institutional network of research teams working...

cur

Quarterly Research Grant Funding Programme We fund internationally and accept applications from academics and commercial entities. However, the costs in commercial applications should be justified...

demoucelle

The Demoucelle Parkinson Charity partners with the Michael J. Fox Foundation for Parkinson’s Research and applies the following project selection criteria:

Frontespizio

We’re thrilled to share the latest publication from our Working Group 3 (WG3) at IMMUPARKNET COST Action 21117, published in npj Parkinson’s Disease! Entitled “Recommendations...